The Quantellect read.As of Nov 19, 2026, 7 active firms cover Privia Health Group Inc: 6 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $24.00 to $34.00, a moderate spread. The average target of $30.29 sits 23% above the current $24.61. The rating mix has stayed broadly stable, with Buy-side ratings easing from 9 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.26 next quarter toward $1.03 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy686%
Neutral114%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$30.29
+23.1% upside
Average target across 7 active firms as of Nov 19, 2026 vs $24.61 current
Highest Target$34.00
Average Target$30.29
Lowest Target$24.00
Detailed analyst forecasts for PRVA
Showing 1–7 of 7 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 6 of 7 active firms rate PRVA a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PRVA EPS & revenue forecast
EPS · NEXT QUARTER
$0.26
Range $0.20 – $0.33 · 5 analysts · +35% YoY
Next period, 5 analysts expect Privia Health Group Inc to earn $0.26 a share (range $0.20 – $0.33), versus $0.19 a year earlier. Full-year consensus is $0.85, growing to $1.03 the year after.
REVENUE · NEXT QUARTER
$666.1M
Range $633.0M – $707.7M · 5 analysts · +10% YoY
Revenue is expected to reach $666.1M (range $633.0M – $707.7M), +10.3% year-over-year. Full-year consensus is $2.5B, rising to $2.8B next year.
Top analysts covering Privia Health Group Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PRVA.
#1
David Scharf
JMP Securities · Rank #193
Buy
$30.00+21.9% to target
Overall win rate
48%
+ Follow
#2
Richard Close
Canaccord Genuity · Rank #249
Buy
$33.00+34.1% to target
Overall win rate
37%
+ Follow
#3
AR
A.J. Rice
UBS · Rank #365
Buy
$31.00+26.0% to target
Overall win rate
35%
+ Follow
#4
Andrew Mok
Barclays · Rank #385
Neutral
$24.00-2.5% to target
Overall win rate
39%
+ Follow
#5
Constantine Davides
JMP Securities · Rank #454
Buy
$31.00+26.0% to target
Overall win rate
32%
+ Follow
PRVA stock forecast FAQ
What is PRVA's average 12-month price target?+
The 7 active firms with a live target average $30.29 for Privia Health Group Inc over the next 12 months, ranging from a $34.00 high to a $24.00 low, as of Nov 19, 2026.
Is PRVA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for PRVA?+
The Street-high target is $34.00 (Canaccord Genuity), and the Street-low is $24.00 (Barclays). The average of all 7 active-firm targets is $30.29.
How many active Wall Street firms cover PRVA?+
7 active firms have a recognized rating on Privia Health Group Inc as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PRVA?+
Among analysts who currently cover PRVA, David Scharf of JMP Securities has the strongest overall Quantellect track record (Rank #193). Their current call is Buy with a $30.00 target.
What is Privia Health Group Inc's projected EPS for next quarter?+
The consensus estimate is $0.26 per share (range $0.20 – $0.33) across 5 analysts. Full-year EPS is projected at $0.85, rising to $1.03 the following year.
How much revenue is Privia Health Group Inc expected to report next quarter?+
Consensus revenue is $666.1M (range $633.0M – $707.7M). Full-year revenue is projected at $2.5B, growing to $2.8B next year.
Have analysts been upgrading or downgrading PRVA lately?+
As of Nov 19, 2026, 6 of 7 active firms rate PRVA a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PRVA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.